This is one risk that has always concerned me. I've said for many years that PNV should be a long term blue chip Australian owned share. Novosorb applications are effectively endless and we are only now touching the surface of our first almost billion $ market... hence even now I'd vote against a buy out at below $2/share... the medical advantages Novosorb brings are nothing short of extraordinary... let's keep the IP locally owned... if we can...
...hoping for updates on breast reconstruction/hernia/diabetes cure/drug elucidating pellets... perhaps before the AGM??
Gav
PNV Price at posting:
27.5¢ Sentiment: Buy Disclosure: Held
